Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Abeona Therapeutics (ABEO)

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,472
  • Shares Outstanding, K 101,227
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -84,230 K
  • 60-Month Beta 1.43
  • Price/Sales 12.55
  • Price/Cash Flow N/A
  • Price/Book 1.63
Trade ABEO with:

Options Overview

Details
  • Implied Volatility 246.70%
  • Historical Volatility 54.26%
  • IV Percentile 71%
  • IV Rank 21.97%
  • IV High 768.34% on 11/10/20
  • IV Low 99.86% on 04/06/21
  • Put/Call Vol Ratio 0.03
  • Today's Volume 511
  • Volume Avg (30-Day) 132
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,666
  • Open Int (30-Day) 3,812

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.17
  • Prior Year -0.08
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +3.42%
on 09/17/21
1.3600 -11.03%
on 09/07/21
+0.0400 (+3.42%)
since 08/20/21
3-Month
1.1101 +9.00%
on 08/17/21
1.7500 -30.86%
on 06/25/21
-0.4900 (-28.82%)
since 06/18/21
52-Week
0.9895 +22.28%
on 11/03/20
3.7899 -68.07%
on 02/09/21
-0.8700 (-41.83%)
since 09/18/20

Most Recent Stories

More News
Abeona Therapeutics to Present at Upcoming Investor Conferences

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company's management will present and conduct one-on-one meetings at the...

ABEO : 1.2100 (+0.83%)
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Edward Carr as Chief Financial Officer and Principal Financial Officer, effective...

ABEO : 1.2100 (+0.83%)
Abeona Therapeutics Reports Second Quarter Financial Results

Second clinical trial site activated in EB-101 pivotal Phase 3 VIITAL(TM) study

ABEO : 1.2100 (+0.83%)
Abeona Therapeutics: Q2 Earnings Snapshot

DALLAS (AP) _ Abeona Therapeutics Inc. (ABEO) on Wednesday reported a loss of $15.2 million in its second quarter.

ABEO : 1.2100 (+0.83%)
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)

Transpher A; pivotal study for intended registration of ABO-102 for MPS IIIA disease

ABEO : 1.2100 (+0.83%)
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene therapy, today announced magnetic resonance imaging (MRI) data from the Phase 1/2 Transpher A clinical study indicating that ABO-102...

ABEO : 1.2100 (+0.83%)
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL(TM) Study for Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL(TM) study of its...

ABEO : 1.2100 (+0.83%)
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced updated Phase 1/2a clinical trial results up to six years following treatment with Abeona's...

ABEO : 1.2100 (+0.83%)
Thinking about buying stock in La Jolla Pharmaceutical, The GEO Group, Abeona Therapeutics, Sellas Life Sciences, or Naked Brand?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LJPC, GEO, ABEO, SLS, and NAKD.

SLS : 9.79 (-7.03%)
ABEO : 1.2100 (+0.83%)
LJPC : 4.06 (+1.00%)
NAKD : 0.5468 (-6.93%)
GEO : 7.00 (-0.14%)
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Michael Amoroso, President and Chief Executive Officer, will present at the Jefferies Virtual...

ABEO : 1.2100 (+0.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Key Turning Points

3rd Resistance Point 1.2760
2nd Resistance Point 1.2480
1st Resistance Point 1.2290
Last Price 1.2100
1st Support Level 1.1820
2nd Support Level 1.1540
3rd Support Level 1.1350

See More

52-Week High 3.7899
Fibonacci 61.8% 2.7201
Fibonacci 50% 2.3897
Fibonacci 38.2% 2.0593
Last Price 1.2100
52-Week Low 0.9895

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar